One of the most significant findings from the RECOVERY trial is that dexamethasone significantly reduces mortality in patients requiring oxygen or ventilatory support. Conversely, treatments like hydroxychloroquine and lopinavir-ritonavir were found to be ineffective in treating COVID-19, leading to the discontinuation of these arms of the trial.
